Supreme Court Opinion Delivers Blow to Drug Patent Holders.

The article discusses the disagreement of drug patent stakeholders regarding the opinion of the Supreme Court of the U.S. of favoring generic drug manufacturers and advocates for lower drug prices in a patent-law case. Topics discussed include the focus of the case "Cuozzo Speed Technologies v Lee," the difference between inter partes review (IPR) process and the federal court system, and an amicus brief filed by America's Health Insurance Plans and Generic Pharmaceutical Association.